Objective: The objective of the present study was to develop colon targeted pulsatile drug delivery system of Rizatriptan benzoate for the treatment of migraine. Method: Drug excipient interaction was carried by UV spectroscopy, FT-IR and DSC. Granules were prepared by wet granulation method. Physicochemical characteristics of Rizatriptan benzoate was carried out by flow properties and drug content. From the obtained results the formulation was selected for further preparation of pulsatile capsule with 100mg hydrogel plug. Prepared pulsincap was coated with 5% CAP. The pulsincap was evaluated for in-vitro dissolution studies and release kinetics. Results: F6 formulation was optimized. FTIR and DSC has shown no interaction between polymer and Rizatriptan benzoate. Cross-linked gelatine capsule were evaluated and confirmed that 8 hrs formaldehyde treatment was sufficient.100mg hydrogel plug was optimized Hardness and thickness of the plug controlled lag time. Granules showed good flow properties and drug content were found to be in the range of 95.4±0.56 to 98.3±0.56%. The results indicated that drug content was uniform. In-vitro release studies revealed that increasing the polymer content resulted in sustained release. Value of n in Korsmeyer-Peppas Equation is greater than 1 hence, formulation were follows swelling controlled super case II transport. Conclusion: Present pulsincap formulation study conclude that optimized F6 batch of Rizatriptan benzoate successfully targeted to colon for the treatment of migraine. Drug release over a period of 5-18 hrs, can be achieved from treated gelatine capsule and hydrogel plug.